Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · IEX Real-Time Price · USD
17.59
-1.04 (-5.58%)
At close: Mar 28, 2024, 4:00 PM
17.10
-0.49 (-2.80%)
After-hours: Mar 28, 2024, 5:25 PM EDT

Enliven Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Cash & Equivalents
100.275.5948.3147.74.947.38
Short-Term Investments
153.01041.9740.5223.970
Cash & Cash Equivalents
253.275.5990.2888.2228.917.38
Cash Growth
234.97%-16.27%2.33%205.19%291.59%-
Other Current Assets
12.952.162.422.181.720.32
Total Current Assets
266.1577.7592.790.4130.627.71
Property, Plant & Equipment
1.061.520.780.350.440
Other Long-Term Assets
4.654.030.180.092.230
Total Long-Term Assets
5.725.550.950.442.670
Total Assets
271.8783.393.6590.8433.37.71
Accounts Payable
0.533.442.361.971.660.91
Current Debt
000.25000
Other Current Liabilities
25.366.284.64.282.540.92
Total Current Liabilities
25.899.727.216.254.21.83
Long-Term Debt
000.41000
Other Long-Term Liabilities
0.070.6600.160.180
Total Long-Term Liabilities
0.070.660.410.160.180
Total Liabilities
25.9610.377.626.414.381.83
Total Debt
000.65000
Retained Earnings
-154.45-82.86-147.5-96.11-54.75-31.29
Comprehensive Income
0.140-0.0200.030
Shareholders' Equity
245.91-76.8386.0384.44-48.85-26.32
Net Cash / Debt
253.275.5989.6388.2228.917.38
Net Cash / Debt Growth
234.97%-15.66%1.59%205.19%291.59%-
Net Cash Per Share
7.1224.1916.5525.34164.6142.04
Working Capital
240.2668.0485.4984.1626.435.87
Book Value Per Share
6.92-24.5915.8924.25-278.16-149.85
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).